vs
爱德华生命科学（EW）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是Revvity的2.1倍（$1.6B vs $772.1M），爱德华生命科学净利率更高（23.1% vs 12.7%，领先10.4%），爱德华生命科学同比增速更快（16.7% vs 5.9%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs 9.0%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EW vs RVTY — 直观对比
营收规模更大
EW
是对方的2.1倍
$772.1M
营收增速更快
EW
高出10.8%
5.9%
净利率更高
EW
高出10.4%
12.7%
两年增速更快
EW
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $772.1M |
| 净利润 | $380.7M | $98.4M |
| 毛利率 | 78.0% | — |
| 营业利润率 | 1.8% | 14.5% |
| 净利率 | 23.1% | 12.7% |
| 营收同比 | 16.7% | 5.9% |
| 净利润同比 | 6.8% | 3.9% |
| 每股收益（稀释后） | $0.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWRVTY
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $772.1M | ||
| Q3 25 | $1.6B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.4B | $684.0M | ||
| Q2 24 | $1.4B | $691.7M |
净利润EWRVTY
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | $98.4M | ||
| Q3 25 | $291.1M | $46.7M | ||
| Q2 25 | $333.2M | $53.9M | ||
| Q1 25 | $358.0M | $42.2M | ||
| Q4 24 | $385.6M | $94.6M | ||
| Q3 24 | $3.1B | $94.4M | ||
| Q2 24 | $366.3M | $55.4M |
毛利率EWRVTY
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | — | ||
| Q3 25 | 77.8% | 53.6% | ||
| Q2 25 | 77.5% | 54.5% | ||
| Q1 25 | 78.7% | 56.5% | ||
| Q4 24 | 78.9% | — | ||
| Q3 24 | 80.6% | 56.3% | ||
| Q2 24 | 79.9% | 55.7% |
营业利润率EWRVTY
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 14.5% | ||
| Q3 25 | 19.8% | 11.7% | ||
| Q2 25 | 26.8% | 12.6% | ||
| Q1 25 | 27.9% | 10.9% | ||
| Q4 24 | 22.6% | 16.3% | ||
| Q3 24 | 25.9% | 14.3% | ||
| Q2 24 | 26.8% | 12.4% |
净利率EWRVTY
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | 12.7% | ||
| Q3 25 | 18.7% | 6.7% | ||
| Q2 25 | 21.7% | 7.5% | ||
| Q1 25 | 25.3% | 6.4% | ||
| Q4 24 | 27.8% | 13.0% | ||
| Q3 24 | 226.7% | 13.8% | ||
| Q2 24 | 26.7% | 8.0% |
每股收益（稀释后）EWRVTY
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $0.86 | ||
| Q3 25 | $0.50 | $0.40 | ||
| Q2 25 | $0.56 | $0.46 | ||
| Q1 25 | $0.61 | $0.35 | ||
| Q4 24 | $0.65 | $0.77 | ||
| Q3 24 | $5.13 | $0.77 | ||
| Q2 24 | $0.61 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | — | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $919.9M | ||
| Q3 25 | $3.8B | $931.4M | ||
| Q2 25 | $4.1B | $991.8M | ||
| Q1 25 | $3.9B | $1.1B | ||
| Q4 24 | $4.0B | $1.2B | ||
| Q3 24 | $4.4B | $1.2B | ||
| Q2 24 | $2.0B | $2.0B |
股东权益EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | $10.3B | $7.3B | ||
| Q3 25 | $10.2B | $7.4B | ||
| Q2 25 | $10.5B | $7.6B | ||
| Q1 25 | $10.1B | $7.6B | ||
| Q4 24 | $10.0B | $7.7B | ||
| Q3 24 | $9.5B | $7.9B | ||
| Q2 24 | $7.4B | $7.9B |
总资产EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | $13.7B | $12.2B | ||
| Q3 25 | $13.3B | $12.1B | ||
| Q2 25 | $13.5B | $12.4B | ||
| Q1 25 | $13.0B | $12.4B | ||
| Q4 24 | $13.1B | $12.4B | ||
| Q3 24 | $13.0B | $12.8B | ||
| Q2 24 | $10.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | $450.9M | $182.0M | ||
| Q3 25 | $573.7M | $138.5M | ||
| Q2 25 | $290.2M | $134.3M | ||
| Q1 25 | $280.4M | $128.2M | ||
| Q4 24 | $-127.5M | $174.2M | ||
| Q3 24 | $351.8M | $147.9M | ||
| Q2 24 | $371.5M | $158.6M |
自由现金流EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | $353.5M | $161.8M | ||
| Q3 25 | $516.2M | $120.0M | ||
| Q2 25 | $240.9M | $115.5M | ||
| Q1 25 | $224.4M | $112.2M | ||
| Q4 24 | $-177.3M | $149.8M | ||
| Q3 24 | $299.9M | $125.6M | ||
| Q2 24 | $286.1M | $136.6M |
自由现金流率EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | 22.5% | 21.0% | ||
| Q3 25 | 33.2% | 17.2% | ||
| Q2 25 | 15.7% | 16.0% | ||
| Q1 25 | 15.9% | 16.9% | ||
| Q4 24 | -12.8% | 20.5% | ||
| Q3 24 | 22.1% | 18.4% | ||
| Q2 24 | 20.9% | 19.7% |
资本支出强度EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 2.6% | ||
| Q3 25 | 3.7% | 2.6% | ||
| Q2 25 | 3.2% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 3.6% | 3.4% | ||
| Q3 24 | 3.8% | 3.3% | ||
| Q2 24 | 6.2% | 3.2% |
现金转化率EWRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.94× | 1.85× | ||
| Q3 25 | 1.97× | 2.97× | ||
| Q2 25 | 0.87× | 2.49× | ||
| Q1 25 | 0.78× | 3.03× | ||
| Q4 24 | -0.33× | 1.84× | ||
| Q3 24 | 0.11× | 1.57× | ||
| Q2 24 | 1.01× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EW
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
